Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NBTY's Julian Graves acquisition clears

This article was originally published in The Tan Sheet

Executive Summary

U.K. regulators July 22 clear supplement firm NBTY's acquisition of 350-store U.K. confectionery chain Julian Graves. The OK followed provisional findings by the Competition Commission, the Ronkonkoma, N.Y.-based firm said. The firm purchased Julian Graves in September for $25 million, but the commission raised concerns the acquisition could obstruct competition in the market for seeds, nuts and dried fruit (1"The Tan Sheet" July 20, 2009). NBTY said it expects the commission to make a final decision before Sept. 4

You may also be interested in...



NBTY Not "Trigger Happy," But Acquisitions Stay In Its Crosshairs

NBTY hopes to remain a supplement industry giant in part by continuing to acquire other businesses, a strategy with an improving outlook as opportunities emerge during the global economic slump

EU Biosimilar Filings, Opinions And Approvals

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Executives On The Move: Alligator Bioscience Appoints New Chief Business Officer

American Injectables gets a new CEO, while Hemostemix names a new chief medical officer.

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel